PUBLISHER: IMARC | PRODUCT CODE: 1347567
PUBLISHER: IMARC | PRODUCT CODE: 1347567
The global molecular diagnostics market size reached US$ 18.5 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 27.4 Billion by 2028, exhibiting a growth rate (CAGR) of 6.5% during 2023-2028.
Molecular diagnostics refers to a set of laboratory tests that sequences the deoxyribonucleic acid (DNA), ribonucleic acid (RNA), or cell proteins of an individual to analyze biomarkers of potential diseases. It assists in diagnosing and monitoring infections and diseases, detecting risks, and assessing therapy response. In recent years, molecular diagnostics has rapidly gained traction in oncology, pharmacogenomics, microbiology, infectious diseases, genetic disease screening, and blood screening. With recent advancements, molecular diagnostics has become an essential aspect of patient-tailored interventions and therapeutics, which is escalating its demand across the globe.
Molecular diagnostics is widely used by hospitals, laboratories, and research institutes for early detection of diseases, coagulation, and human leukocyte antigen typing. As a result, the rising prevalence of chronic conditions, such as cancer, cardiovascular diseases (CVDs), neurological disorders, and infectious diseases, represents the primary factor driving the market growth. Besides this, the growing geriatric population that is more susceptible to developing numerous medical ailments and the widespread adoption of point-of-care (POC) testing devices are catalyzing the product demand. Additionally, the recent outbreak of coronavirus disease (COVID-19) has accelerated the adoption of molecular diagnostic methods, such as polymerase chain reaction (PCR), for COVID-19 testing. Along with this, several favorable initiatives undertaken by the governing agencies and regulatory authorities of various countries, such as fast approvals of diagnostic products to help curb the spread of the virus, are also propelling the market growth. Furthermore, the leading players are making heavy investments to launch innovative diagnostic devices that offer enhanced accuracy, flexibility, cost-effectiveness, and faster results to expand their product portfolio and gain a competitive edge. Other factors, including the escalating demand for personalized treatment, the emerging trend of preventive medicine, improving healthcare infrastructure, and technological advancements, are also creating a positive market outlook.
IMARC Group provides an analysis of the key trends in each sub-segment of the global molecular diagnostics market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product, technology, application and end users.
Reagents and Kits
Instruments
Software and Services
Polymerase Chain Reactions (PCR)
Hybridization
DNA Sequencing
Microarray
Isothermal Nucleic Acid Amplification Technology (INAAT)
Others
Infectious Diseases Diagnostics
Oncology
Genetic Testing
Blood Screening
Others
Hospitals
Laboratories
Others
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Agilent Technologies Inc., Becton Dickinson and Company, Biomerieux SA, Danaher Corporation, Diasorin Molecular LLC (DiaSorin), F. Hoffmann-La Roche AG (Roche Holding AG), Hologic Inc., Illumina Inc., Myriad Genetics Inc., Qiagen, Quidel Corporation and Thermo Fisher Scientific.